# Suzhou BlueHorse Therapeutics

Source: https://onco.cc/companies/suzhou-bluehorse-therapeutics/  
OnCo record `suzhou-bluehorse-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Suzhou BlueHorse Therapeutics is a China-based cell therapy company that leads 2 cancer trials in OnCo, testing the tumour-infiltrating lymphocyte product LM103 in non-small-cell lung cancer and melanoma.

## Summary

Suzhou BlueHorse Therapeutics is a Suzhou-based cell therapy developer. The ClinicalTrials.gov registry lists it as lead sponsor of phase 2 trials of LM103, a tumour-infiltrating lymphocyte (TIL) product, in non-small-cell lung cancer and melanoma. Its website could not be reached, so company facts here are limited to the registry. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo: NCT07444437 (phase 2, A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung C...) and NCT07310784 (phase 2, A Phase II Trial of LM103 in Advanced Melanoma). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: Suzhou Lanma Biotechnology
- Tags: ctgov-sponsor
- HQ: Suzhou
- Type: cell-therapy

## Sources

- ClinicalTrials.gov: trials led by Suzhou BlueHorse Therapeutics: https://clinicaltrials.gov/search?lead=Suzhou%20BlueHorse%20Therapeutics%20Co.%2C%20Ltd.

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Dacarbazine](https://onco.cc/drugs/dacarbazine/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Temozolomide](https://onco.cc/drugs/temozolomide/)
- trials: [A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer](https://onco.cc/trials/nct07444437/), [A Phase II Trial of LM103 in Advanced Melanoma](https://onco.cc/trials/nct07310784/)

---
JSON: https://onco.cc/api/v1/entities/suzhou-bluehorse-therapeutics.json